JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

7.22 -2.04

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.19

Max

7.37

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

118.571

84.243

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+60.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-557M

1.3B

Iepriekšējā atvēršanas cena

9.26

Iepriekšējā slēgšanas cena

7.22

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. febr. 23:57 UTC

Tirgus saruna

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026. g. 8. febr. 23:47 UTC

Tirgus saruna

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026. g. 8. febr. 23:43 UTC

Tirgus saruna

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026. g. 8. febr. 23:26 UTC

Tirgus saruna

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026. g. 8. febr. 21:43 UTC

Tirgus saruna

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026. g. 8. febr. 21:16 UTC

Tirgus saruna

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026. g. 8. febr. 21:15 UTC

Tirgus saruna

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. febr. 02:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Money, High Anxiety -- Barrons.com

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. febr. 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026. g. 6. febr. 21:22 UTC

Tirgus saruna

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026. g. 6. febr. 21:17 UTC

Peļņas

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. g. 6. febr. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. febr. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026. g. 6. febr. 21:13 UTC

Peļņas

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026. g. 6. febr. 21:13 UTC

Peļņas

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026. g. 6. febr. 21:04 UTC

Tirgus saruna

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026. g. 6. febr. 20:34 UTC

Peļņas

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

60.03% augšup

Prognoze 12 mēnešiem

Vidējais 11.57 USD  60.03%

Augstākais 13 USD

Zemākais 9 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat